A case report of sofosbuvir and daclatasvirto treat a patient with acute hepatitis C virus genotype 2 monoinfection. Issue 15 (April 2018)

• Record Type: Journal Article
• Authors: Li, Chen; Hu, JinHua
• Other Names: NA. section editor.
• Is Part Of: Medicine. Volume 97:Issue 15(2018)
• Publication Date: 2018-04
• Subjects: acute hepatitis C (AHC) -- case report -- daclatasvir (DCV) -- direct-acting antivirals (DAAs) -- sofosbuvir (SOF); Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000010416
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Rationale: Direct-acting antivirals (DAAs) are the first-line treatment for patients with chronic hepatitis C virus (HCV) infection. However, its effects on patients with acute HCV infection are poorly understood, and the data for treatment of DAAs for genotype 2 acute monoinfection patients with HCV are lacking. Patient concerns: In this case report, a 26 year-old Chinese female acquired a tattoo and developed fatigue, nausea, and anorexia. Laboratory tests showed abnormal liver function. Diagnoses: Five months after the patient acquired a tattoo, laboratory tests showed anti-HCV antibody titers were 26.0 s/co, HCV RNA was 5.74×10 5 IU/mL, and HCV genotype was 2a. The patient was diagnosed with acute hepatitis C (AHC). Interventions: HCV RNA did not have spontaneous clearance 12 weeks after the infection of the patient. The patient received sofosbuvir (SOF) and daclatasvir (DCV) combination treatment for 12 weeks. Outcomes: Laboratory tests showed HCV RNA was undetectable at weeks 4, and anti-HCV antibody was in seroconversion at weeks 12 during treatment. The patient achieved a sustained virological response 36 weeks after the end of treatment. Lessons: Patients with acute HCV genotype 2 monoinfection would benefit from antiviral treatment with SOF and DCV.